Expression of Akt and Mdm2 in human esophageal squamous cell carcinoma

Experimental and Molecular Pathology

Volumn 87, Issue 1, 2009, Pages 42-47

  Takahashi, Ken ^a   Miyashita, Masao ^a   Makino, Hiroshi ^a   Akagi, Ichiro ^a   Orita, Hajime ^b   Hagiwara, Nobutoshi ^a   Nomura, Tsutomu ^a   Gabrielson, Edward W ^c   Tajiri, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Akt1; Akt2; Akt3; Esophageal carcinoma; Mdm2; siRNA

Indexed keywords

ISOENZYME; MESSENGER RNA; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67649442836     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2008.11.013     Document Type: Article

References (32)

1. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G., and Testa J.R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64 (1995) 280-285
2. Bellacosa A., Testa J.R., Moore R., and Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol. Ther. 3 (2004) 268-275
3. Cahilly-Snyder L., Yang-Feng T., Francke U., and George D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13 (1987) 235-244
4. Cheng J.Q., Ruggeri B., Klein W.M., Sonoda G., Altomare D.A., Watson D.K., and Testa J.R. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3636-3641
5. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev. 13 (1999) 2905-2927
6. Ding Y., Shimada Y., Kano M., Itami A., Kawabe A., Maeda M., Li Z., Hong T., Sato F., Kaganoi J., and Imamura M. PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Int. J. Oncol. 17 (2000) 695-699
7. Fakharzadeh S.S., Trusko S.P., and George D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J. 10 (1991) 1565-1569
8. Florenes V.A., Maelandsmo G.M., Forus A., Andreassen A., Myklebost O., and Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst. 86 (1994) 1297-1302
9. Haines D.S., Landers J.E., Engle L.J., and George D.L. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell. Biol. 14 (1994) 1171-1178
10. Haitel A., Wiener H.G., Baethge U., Marberger M., and Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 6 (2000) 1840-1844
11. Iwakuma T., and Lozano G. MDM2, an introduction. Mol. Cancer Res. 1 (2003) 993-1000
12. Japanese Society for Esophageal, D., 1999. Guide lines for the clinical and pathologic studies for carcinoma of the esophagus. 9th ed. Kanehara and Co., Ltd: 23.
13. Lee B.L., Lee H.S., Jung J., Cho S.J., Chung H.Y., Kim W.H., Jin Y.W., Kim C.S., and Nam S.Y. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin. Cancer Res. 11 (2005) 2518-2525
14. Lim W.T., Zhang W.H., Miller C.R., Watters J.W., Gao F., Viswanathan A., Govindan R., and McLeod H.L. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol. Rep. 17 (2007) 853-857
15. Nakatani K., Thompson D.A., Barthel A., Sakaue H., Liu W., Weigel R.J., and Roth R.A. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J. Biol. Chem. 274 (1999) 21528-21532
16. Negoro K., Takahashi S., Kinouchi Y., Takagi S., Hiwatashi N., Ichinohasama R., Shimosegawa T., and Toyota T. Analysis of the PTEN gene mutation in polyposis syndromes and sporadic gastrointestinal tumors in Japanese patients. Dis Colon Rectum. 43 (2000) 29-33
17. Nishihira T., Hashimoto Y., Katayama M., Mori S., and Kuroki T. Molecular and cellular features of esophageal cancer cells. J. Cancer Res. Clin. Oncol. 119 (1993) 441-449
18. Ogawara Y., Kishishita S., Obata T., Isazawa Y., Suzuki T., Tanaka K., Masuyama N., and Gotoh Y. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277 (2002) 21843-21850
19. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., and Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358 (1992) 80-83
20. Olson D.C., Marechal V., Momand J., Chen J., Romocki C., and Levine A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 8 (1993) 2353-2360
21. Piette J., Neel H., and Marechal V. Mdm2: keeping p53 under control. Oncogene 15 (1997) 1001-1010
22. Pinto A.E., Andre S., Laranjeira C., and Soares J. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology 37 (2005) 45-50
23. Saito H., Tsujitani S., Oka S., Ikeguchi M., Maeta M., and Kaibara N. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann. Surg. Oncol. 9 (2002) 450-456
24. Sarbia M., Porschen R., Borchard F., Horstmann O., Willers R., and Gabbert H.E. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74 (1994) 2218-2223
25. Soslow R.A., Altorki N.K., Yang G., Xie D., and Yang C.S. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod. Pathol. 12 (1999) 580-586
26. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5034-5037
27. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
28. Sun M., Wang G., Paciga J.E., Feldman R.I., Yuan Z.Q., Ma X.L., Shelley S.A., Jove R., Tsichlis P.N., Nicosia S.V., and Cheng J.Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159 (2001) 431-437
29. Tachibana M., Shibakita M., Ohno S., Kinugasa S., Yoshimura H., Ueda S., Fujii T., Rahman M.A., Dhar D.K., and Nagasue N. Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94 (2002) 1955-1960
30. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10983-10985
31. Yu Z., Weinberger P.M., Sasaki C., Egleston B.L., Speier W.F.t., Haffty B., Kowalski D., Camp R., Rimm D., Vairaktaris E., Burtness B., and Psyrri A. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 553-558
32. Zhou B.P., Liao Y., Xia W., Spohn B., Lee M.H., and Hung M.C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3 (2001) 245-252